Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Abstract Acute myeloid leukaemia (AML) is a highly aggressive and devastating malignancy of the bone marrow and blood. For decades, intensive chemotherapy has been the frontline treatment for AML but has yielded only poor patient outcomes as exemplified by a 5-year survival rate of < 30%, even in...
| Published in: | Cell Death and Disease |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-06-01
|
| Online Access: | https://doi.org/10.1038/s41419-024-06810-7 |